Avenue Therapeutics, Inc.

About Avenue Therapeutics, Inc.

Avenue Therapeutics is a specialty pharmaceutical company dedicated to developing and commercializing therapies for neurologic diseases. Their mission is to deliver impactful treatments that address unmet patient needs and transform outcomes through innovative, first-in-class, and best-in-class programs.

Products & Services

BAER-101:A therapy under development for neurologic diseases.

IV Tramadol:An intravenous formulation of tramadol for potential treatment in neurologic conditions.

AJ201:A therapeutic candidate in the company's pipeline targeting neurologic disorders.

Specialties

Neurologic disease therapies Development of first-in-class treatments Commercialization of best-in-class programs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4400000 MR: - FA: 4.4 million FAN: 4400000	D: 2024-04-29 FD: 2024-04-29	-
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 5000000 MR: - FA: 5.0 million FAN: 5000000	D: 2024-01-05 FD: 2024-01-05	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2023-11-02 FD: 2023-11-02	-
4	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2023-10-31 FD: 2023-10-31	-
5	RT: Registered Direct and Private Placement T: - FT: Registered Direct and Private Placement	A: 3250000 MR: - FA: approximately $3.25 million FAN: 3250000	D: 2023-01-31 FD: 2023-01-31	1 investors
6	RT: Private Placement T: - FT: Private Placement	A: 3250000 MR: - FA: 3.25 Million FAN: 3250000	D: 2023-01-31 FD: 2023-01-31	-
7	RT: Private Placement and Registered Direct Offering T: - FT: Private Placement and Registered Direct Offering	A: 3250000 MR: - FA: approximately $3.25 million FAN: 3250000	D: 2023-01-27 FD: 2023-01-27	1 investors

Warrant Exercise Latest

2024-04-29

$4.4M

Warrant Exercise 2024-01-05

$5.0M

Public Offering 2023-11-02

$5.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jay Kranzler

Chairman

L

Lindsay A. Rosenwald

Director

N

Neil Herskowitz

Director

A

Alexandra MacLean

Chief Executive Officer

C

Curtis Oltmans

Director

F

Faith Charles

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News